interferon - versus placebo - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.74 [0.51, 5.93]< 10%1 study (1/-)18.9 %NAnot evaluable crucial-
deaths 0.92 [0.42, 1.98]< 119%3 studies (3/-)58.9 %lownot evaluable highcrucial-
deaths (time to event analysis only) 1.74 [0.51, 5.93]< 10%1 study (1/-)18.9 %NAnot evaluable crucial-
clinical deterioration 0.65 [0.42, 1.00]< 10%2 studies (2/-)97.4 %NAnot evaluable important-
clinical improvement 1.39 [0.61, 3.14]> 178%2 studies (2/-)78.3 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.01 [0.79, 1.29]> 10%1 study (1/-)53.2 %NAnot evaluable important-
clinical improvement (28-day) 3.15 [1.39, 7.14]> 10%1 study (1/-)99.7 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.00 [0.89, 1.12]> 10%2 studies (2/-)48.1 %some concernnot evaluable moderateimportant-
death or ventilation 0.75 [0.42, 1.34]< 10%2 studies (2/-)83.7 %NAnot evaluable important-
hospital discharge 1.07 [0.90, 1.28]> 10%2 studies (2/-)79.0 %NAnot evaluable important-
hospitalization 1.00 [0.14, 7.34]< 10%1 study (1/-)50.0 %NAnot evaluable important-
Recovery (time to event analysis only) 1.02 [0.81, 1.28]> 10%1 study (1/-)56.7 %NAnot evaluable important-
viral clearance 0.81 [0.56, 1.18]> 10%1 study (1/-)13.7 %NAnot evaluable important-
viral clearance (time to event analysis only) 0.81 [0.56, 1.18]> 10%1 study (1/-)13.7 %NAnot evaluable important-
recovery 2.19 [1.03, 4.67]> 10%1 study (1/-)97.9 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 1.00 [0.14, 7.34]< 10%1 study (1/-)50.0 %NAnot evaluable important-
adverse events 1.33 [0.63, 2.78]< 10%1 study (1/-)22.7 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.